Eliquis and Systemic lupus erythematosus - a phase IV clinical study of FDA data
Systemic lupus erythematosus is found among people who take Eliquis, especially for people who are female, 60+ old, have been taking the drug for 6 - 12 months.
The phase IV clinical study analyzes which people take Eliquis and have Systemic lupus erythematosus. It is created by eHealthMe based on reports of 118,315 people who have side effects when taking Eliquis from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.
With medical big data and AI algorithms, eHealthMe enables everyone to run phase IV clinical trial to detect adverse drug outcomes and monitor effectiveness. Our original studies have been referenced on 600+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Most recently, phase IV clinial trails for COVID 19 vaccines have been added, check here.
118,315 people reported to have side effects when taking Eliquis.
Among them, 90 people (0.08%) have Systemic lupus erythematosus.
What is Eliquis?
Eliquis has active ingredients of apixaban. It is often used in atrial fibrillation/flutter. eHealthMe is studying from 119,696 Eliquis users for its effectiveness, alternative drugs and more.
What is Systemic lupus erythematosus?
Systemic lupus erythematosus (an autoimmune disease, which means the body's immune system mistakenly, attacks healthy tissue) is found to be associated with 2,043 drugs and 1,414 conditions by eHealthMe.
Number of Eliquis and Systemic lupus erythematosus reports submitted per year:
Time on Eliquis when people have Systemic lupus erythematosus *:
- < 1 month: 0.0 %
- 1 - 6 months: 50 %
- 6 - 12 months: 50 %
- 1 - 2 years: 0.0 %
- 2 - 5 years: 0.0 %
- 5 - 10 years: 0.0 %
- 10+ years: 0.0 %
Gender of people who have Systemic lupus erythematosus when taking Eliquis *:
- female: 89.66 %
- male: 10.34 %
Age of people who have Systemic lupus erythematosus when taking Eliquis *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 7.27 %
- 30-39: 9.09 %
- 40-49: 10.91 %
- 50-59: 16.36 %
- 60+: 56.36 %
Common drugs people take besides Eliquis *:
- Benlysta: 21 people, 23.33%
- Fluvastatin: 19 people, 21.11%
- Pentacarinat: 19 people, 21.11%
- Mcp: 16 people, 17.78%
- Opsumit: 12 people, 13.33%
- Morphine: 8 people, 8.89%
- Tracleer: 8 people, 8.89%
- Lasix: 7 people, 7.78%
- Adcirca: 7 people, 7.78%
- Plaquenil: 6 people, 6.67%
Common side effects people have besides Systemic lupus erythematosus *:
- Urinary Tract Infection: 27 people, 30.00%
- Fall: 24 people, 26.67%
- Depression: 22 people, 24.44%
- Thrombocytopenia (decrease of platelets in blood): 22 people, 24.44%
- High Blood Pressure: 22 people, 24.44%
- Sepsis (a severe blood infection that can lead to organ failure and death): 21 people, 23.33%
- Aseptic Necrosis (the death of bone tissue due to a lack of blood supply): 21 people, 23.33%
- Antiphospholipid Syndrome (disorder that manifests clinically as recurrent venous or arterial thrombosis and/or fetal loss): 20 people, 22.22%
- Ulcerative Colitis (inflammatory bowel disease (ibd). it causes swelling, ulcerations, and loss of function of the large intestine): 20 people, 22.22%
- Hyperlipidaemia (presence of excess lipids in the blood): 20 people, 22.22%
Common conditions people have *:
- White Blood Cell Count Decreased: 19 people, 21.11%
- Lymphopenia (an abnormally low level of lymphocytes in the blood): 16 people, 17.78%
- Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 15 people, 16.67%
- Pulmonary Hypertension (increase in blood pressure in the lung artery): 13 people, 14.44%
- Stroke (sudden death of a portion of the brain cells due to a lack of oxygen): 6 people, 6.67%
- Pain: 5 people, 5.56%
- Insomnia (sleeplessness): 4 people, 4.44%
- Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 4 people, 4.44%
- High Blood Pressure: 4 people, 4.44%
- Osteoporosis (bones weak and more likely to break): 3 people, 3.33%
* Approximation only. Some reports may have incomplete information.
Do you take Eliquis and have Systemic lupus erythematosus?Check whether Systemic lupus erythematosus is associated with a drug or a condition
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
Related publications that referenced our studies
- Hania A, "Pyoderma Gangrenosum in a Patient With Systemic Lupus Erythematosus: Case Report", Journal of Medical Cases, 2014 Aug .
- Hu P, Lu L, Hu B, Deng F, Fei WJ, "Cyclophosphamide‐Induced Hypertensive Encephalopathy in a Young Girl With Lupus", The Journal of Clinical Hypertension, 2012 Apr .
Alternative drugs to, pros and cons of Eliquis:
- Eliquis (119,696 reports)
Systemic lupus erythematosus treatments and more:
- Systemic lupus erythematosus (52,473 reports)
COVID vaccines that are related to Systemic lupus erythematosus:
- Systemic lupus erythematosus in Moderna COVID Vaccine
- Systemic lupus erythematosus in Pfizer BioNTech Covid Vaccine
- Systemic lupus erythematosus in Johnson and Johnson Covid Vaccine
How severe was Systemic lupus erythematosus and when was it recovered:
Expand to all the drugs that have ingredients of apixaban:
Common drugs associated with Systemic lupus erythematosus:
All the drugs that are associated with Systemic lupus erythematosus:
- Systemic lupus erythematosus (2,043 drugs)
Common conditions associated with Systemic lupus erythematosus:
All the conditions that are associated with Systemic lupus erythematosus:
- Systemic lupus erythematosus (1,414 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on apixaban (the active ingredients of Eliquis) and Eliquis (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.